The gynaecological management of women on tamoxifen: a national questionnaire survey
Tamoxifen is the standard adjuvant treatment for women with breast carcinoma, decreasing the incidence of contralateral disease. However, the risk of endometrial cancer is increased. To establish current gynaecological management of women receiving tamoxifen in the United Kingdom we conducted a post...
Gespeichert in:
| Veröffentlicht in: | Journal of obstetrics and gynaecology 2004-09, Vol.24 (6), p.675-679 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 679 |
|---|---|
| container_issue | 6 |
| container_start_page | 675 |
| container_title | Journal of obstetrics and gynaecology |
| container_volume | 24 |
| creator | Brockbank, EC Ghaem-Maghami, S Bridges, JE |
| description | Tamoxifen is the standard adjuvant treatment for women with breast carcinoma, decreasing the incidence of contralateral disease. However, the risk of endometrial cancer is increased. To establish current gynaecological management of women receiving tamoxifen in the United Kingdom we conducted a postal questionnaire of consultant gynaecologists, enquiring about frequency of, and methods used to investigate women on tamoxifen. Ninety-five per cent investigate women on tamoxifen only if they are symptomatic. Pelvic ultrasound and endometrial sampling are used for first-line investigation by 68.7%. Interpreting ultrasound findings, endometrial thickness is the parameter regarded as most important. An endometrial thickness of greater than 5 mm is regarded abnormal by 47.8% of respondents and of 4 mm by 23.6%. As there is no consensus of opinion regarding normal values for endometrial thickness, further data are required to ensure consistency when interpreting ultrasound reports of women on tamoxifen. |
| doi_str_mv | 10.1080/01443610400008016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_journals_215715309</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>840558291</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-f43bbf547cf44b3b91b71b23bb11a5e2bd511a14c0b8b56bd9b92acfe909497d3</originalsourceid><addsrcrecordid>eNp9kF9LwzAUxYMobk4_gC8SfK_mLmm7qi8i_oOBL_O53KTJ1tEmM-nUfXszNxgimpccbn7ncHMIOQV2AWzELhkIwTNggsUzYpDtkT7wTCTZqOD7pL9-TyKQ9shRCPMIAUvFIelBBiKPxj6ZTGaaTlcWtXKNm9YKG9qixalute2oM_TDRUWdpR227rM22l5RpBa72tkIvy11WEuLtdc0LP27Xh2TA4NN0Cfbe0BeH-4nd0_J-OXx-e52nCgusi4xgktpUpErI4TksgCZgxzGIQCmeiirNAoQismRTDNZFbIYojK6YIUo8ooPyPkmd-Hd9x7l3C193CqUQ0hzSDkrIgQbSHkXgtemXPi6Rb8qgZXrGstfNUbP2TZ4KVtd7Rzb3iJwswFqa5xv8cP5pio7XDXOG49W1aHk_-Vf_7DPNDbdTKHXux_87f4C38mSyg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>215715309</pqid></control><display><type>article</type><title>The gynaecological management of women on tamoxifen: a national questionnaire survey</title><source>MEDLINE</source><source>Taylor & Francis Journals Complete</source><creator>Brockbank, EC ; Ghaem-Maghami, S ; Bridges, JE</creator><creatorcontrib>Brockbank, EC ; Ghaem-Maghami, S ; Bridges, JE</creatorcontrib><description>Tamoxifen is the standard adjuvant treatment for women with breast carcinoma, decreasing the incidence of contralateral disease. However, the risk of endometrial cancer is increased. To establish current gynaecological management of women receiving tamoxifen in the United Kingdom we conducted a postal questionnaire of consultant gynaecologists, enquiring about frequency of, and methods used to investigate women on tamoxifen. Ninety-five per cent investigate women on tamoxifen only if they are symptomatic. Pelvic ultrasound and endometrial sampling are used for first-line investigation by 68.7%. Interpreting ultrasound findings, endometrial thickness is the parameter regarded as most important. An endometrial thickness of greater than 5 mm is regarded abnormal by 47.8% of respondents and of 4 mm by 23.6%. As there is no consensus of opinion regarding normal values for endometrial thickness, further data are required to ensure consistency when interpreting ultrasound reports of women on tamoxifen.</description><identifier>ISSN: 0144-3615</identifier><identifier>EISSN: 1364-6893</identifier><identifier>DOI: 10.1080/01443610400008016</identifier><identifier>PMID: 16147610</identifier><identifier>CODEN: JOGYDW</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Biopsy ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - prevention & control ; Chemotherapy ; Endometrial Neoplasms - chemically induced ; Endometrial Neoplasms - diagnosis ; Endometrium - diagnostic imaging ; Endometrium - pathology ; Female ; Gynecology ; Gynecology - methods ; Humans ; Postmenopause ; Questionnaires ; Surveys and Questionnaires ; Tamoxifen - adverse effects ; Tamoxifen - therapeutic use ; Ultrasonography</subject><ispartof>Journal of obstetrics and gynaecology, 2004-09, Vol.24 (6), p.675-679</ispartof><rights>2004 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2004</rights><rights>Copyright Carfax Publishing Company Sep 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c346t-f43bbf547cf44b3b91b71b23bb11a5e2bd511a14c0b8b56bd9b92acfe909497d3</citedby><cites>FETCH-LOGICAL-c346t-f43bbf547cf44b3b91b71b23bb11a5e2bd511a14c0b8b56bd9b92acfe909497d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/01443610400008016$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/01443610400008016$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,60436,61221,61402</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16147610$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brockbank, EC</creatorcontrib><creatorcontrib>Ghaem-Maghami, S</creatorcontrib><creatorcontrib>Bridges, JE</creatorcontrib><title>The gynaecological management of women on tamoxifen: a national questionnaire survey</title><title>Journal of obstetrics and gynaecology</title><addtitle>J Obstet Gynaecol</addtitle><description>Tamoxifen is the standard adjuvant treatment for women with breast carcinoma, decreasing the incidence of contralateral disease. However, the risk of endometrial cancer is increased. To establish current gynaecological management of women receiving tamoxifen in the United Kingdom we conducted a postal questionnaire of consultant gynaecologists, enquiring about frequency of, and methods used to investigate women on tamoxifen. Ninety-five per cent investigate women on tamoxifen only if they are symptomatic. Pelvic ultrasound and endometrial sampling are used for first-line investigation by 68.7%. Interpreting ultrasound findings, endometrial thickness is the parameter regarded as most important. An endometrial thickness of greater than 5 mm is regarded abnormal by 47.8% of respondents and of 4 mm by 23.6%. As there is no consensus of opinion regarding normal values for endometrial thickness, further data are required to ensure consistency when interpreting ultrasound reports of women on tamoxifen.</description><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Chemotherapy</subject><subject>Endometrial Neoplasms - chemically induced</subject><subject>Endometrial Neoplasms - diagnosis</subject><subject>Endometrium - diagnostic imaging</subject><subject>Endometrium - pathology</subject><subject>Female</subject><subject>Gynecology</subject><subject>Gynecology - methods</subject><subject>Humans</subject><subject>Postmenopause</subject><subject>Questionnaires</subject><subject>Surveys and Questionnaires</subject><subject>Tamoxifen - adverse effects</subject><subject>Tamoxifen - therapeutic use</subject><subject>Ultrasonography</subject><issn>0144-3615</issn><issn>1364-6893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF9LwzAUxYMobk4_gC8SfK_mLmm7qi8i_oOBL_O53KTJ1tEmM-nUfXszNxgimpccbn7ncHMIOQV2AWzELhkIwTNggsUzYpDtkT7wTCTZqOD7pL9-TyKQ9shRCPMIAUvFIelBBiKPxj6ZTGaaTlcWtXKNm9YKG9qixalute2oM_TDRUWdpR227rM22l5RpBa72tkIvy11WEuLtdc0LP27Xh2TA4NN0Cfbe0BeH-4nd0_J-OXx-e52nCgusi4xgktpUpErI4TksgCZgxzGIQCmeiirNAoQismRTDNZFbIYojK6YIUo8ooPyPkmd-Hd9x7l3C193CqUQ0hzSDkrIgQbSHkXgtemXPi6Rb8qgZXrGstfNUbP2TZ4KVtd7Rzb3iJwswFqa5xv8cP5pio7XDXOG49W1aHk_-Vf_7DPNDbdTKHXux_87f4C38mSyg</recordid><startdate>200409</startdate><enddate>200409</enddate><creator>Brockbank, EC</creator><creator>Ghaem-Maghami, S</creator><creator>Bridges, JE</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>200409</creationdate><title>The gynaecological management of women on tamoxifen: a national questionnaire survey</title><author>Brockbank, EC ; Ghaem-Maghami, S ; Bridges, JE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-f43bbf547cf44b3b91b71b23bb11a5e2bd511a14c0b8b56bd9b92acfe909497d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Chemotherapy</topic><topic>Endometrial Neoplasms - chemically induced</topic><topic>Endometrial Neoplasms - diagnosis</topic><topic>Endometrium - diagnostic imaging</topic><topic>Endometrium - pathology</topic><topic>Female</topic><topic>Gynecology</topic><topic>Gynecology - methods</topic><topic>Humans</topic><topic>Postmenopause</topic><topic>Questionnaires</topic><topic>Surveys and Questionnaires</topic><topic>Tamoxifen - adverse effects</topic><topic>Tamoxifen - therapeutic use</topic><topic>Ultrasonography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brockbank, EC</creatorcontrib><creatorcontrib>Ghaem-Maghami, S</creatorcontrib><creatorcontrib>Bridges, JE</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of obstetrics and gynaecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brockbank, EC</au><au>Ghaem-Maghami, S</au><au>Bridges, JE</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The gynaecological management of women on tamoxifen: a national questionnaire survey</atitle><jtitle>Journal of obstetrics and gynaecology</jtitle><addtitle>J Obstet Gynaecol</addtitle><date>2004-09</date><risdate>2004</risdate><volume>24</volume><issue>6</issue><spage>675</spage><epage>679</epage><pages>675-679</pages><issn>0144-3615</issn><eissn>1364-6893</eissn><coden>JOGYDW</coden><abstract>Tamoxifen is the standard adjuvant treatment for women with breast carcinoma, decreasing the incidence of contralateral disease. However, the risk of endometrial cancer is increased. To establish current gynaecological management of women receiving tamoxifen in the United Kingdom we conducted a postal questionnaire of consultant gynaecologists, enquiring about frequency of, and methods used to investigate women on tamoxifen. Ninety-five per cent investigate women on tamoxifen only if they are symptomatic. Pelvic ultrasound and endometrial sampling are used for first-line investigation by 68.7%. Interpreting ultrasound findings, endometrial thickness is the parameter regarded as most important. An endometrial thickness of greater than 5 mm is regarded abnormal by 47.8% of respondents and of 4 mm by 23.6%. As there is no consensus of opinion regarding normal values for endometrial thickness, further data are required to ensure consistency when interpreting ultrasound reports of women on tamoxifen.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>16147610</pmid><doi>10.1080/01443610400008016</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0144-3615 |
| ispartof | Journal of obstetrics and gynaecology, 2004-09, Vol.24 (6), p.675-679 |
| issn | 0144-3615 1364-6893 |
| language | eng |
| recordid | cdi_proquest_journals_215715309 |
| source | MEDLINE; Taylor & Francis Journals Complete |
| subjects | Biopsy Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - prevention & control Chemotherapy Endometrial Neoplasms - chemically induced Endometrial Neoplasms - diagnosis Endometrium - diagnostic imaging Endometrium - pathology Female Gynecology Gynecology - methods Humans Postmenopause Questionnaires Surveys and Questionnaires Tamoxifen - adverse effects Tamoxifen - therapeutic use Ultrasonography |
| title | The gynaecological management of women on tamoxifen: a national questionnaire survey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T12%3A25%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20gynaecological%20management%20of%20women%20on%20tamoxifen:%20a%20national%20questionnaire%20survey&rft.jtitle=Journal%20of%20obstetrics%20and%20gynaecology&rft.au=Brockbank,%20EC&rft.date=2004-09&rft.volume=24&rft.issue=6&rft.spage=675&rft.epage=679&rft.pages=675-679&rft.issn=0144-3615&rft.eissn=1364-6893&rft.coden=JOGYDW&rft_id=info:doi/10.1080/01443610400008016&rft_dat=%3Cproquest_infor%3E840558291%3C/proquest_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=215715309&rft_id=info:pmid/16147610&rfr_iscdi=true |